DE60238038D1 - Das Überleben dopaminerger Neuronen fördernde Faktoren und deren Verwendungen - Google Patents

Das Überleben dopaminerger Neuronen fördernde Faktoren und deren Verwendungen

Info

Publication number
DE60238038D1
DE60238038D1 DE60238038T DE60238038T DE60238038D1 DE 60238038 D1 DE60238038 D1 DE 60238038D1 DE 60238038 T DE60238038 T DE 60238038T DE 60238038 T DE60238038 T DE 60238038T DE 60238038 D1 DE60238038 D1 DE 60238038D1
Authority
DE
Germany
Prior art keywords
methods
manf
survival
dopaminergic neuron
promoting factors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60238038T
Other languages
English (en)
Inventor
John W Commissiong
Andrei A Raibekas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amarantus Therapeutics Inc
Original Assignee
CNS Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23061211&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60238038(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by CNS Therapeutics LLC filed Critical CNS Therapeutics LLC
Application granted granted Critical
Publication of DE60238038D1 publication Critical patent/DE60238038D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Psychology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DE60238038T 2001-03-20 2002-03-20 Das Überleben dopaminerger Neuronen fördernde Faktoren und deren Verwendungen Expired - Lifetime DE60238038D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27751601P 2001-03-20 2001-03-20
PCT/CA2002/000373 WO2002074956A2 (en) 2001-03-20 2002-03-20 Dopaminergic neuronal survival-promoting factors and uses thereof

Publications (1)

Publication Number Publication Date
DE60238038D1 true DE60238038D1 (de) 2010-12-02

Family

ID=23061211

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60238038T Expired - Lifetime DE60238038D1 (de) 2001-03-20 2002-03-20 Das Überleben dopaminerger Neuronen fördernde Faktoren und deren Verwendungen

Country Status (9)

Country Link
US (5) US20020182198A1 (de)
EP (1) EP1373502B8 (de)
JP (1) JP2004528835A (de)
AT (1) ATE485377T1 (de)
CA (1) CA2441740A1 (de)
DE (1) DE60238038D1 (de)
DK (1) DK1373502T3 (de)
ES (1) ES2353490T3 (de)
WO (1) WO2002074956A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020182198A1 (en) 2001-03-20 2002-12-05 Commissiong John W. Dopaminergic neuronal survival-promoting factors and uses thereof
US7452969B2 (en) 2002-08-30 2008-11-18 Licentia Ltd Neurotrophic factor protein and uses thereof
EP1644406B1 (de) 2003-07-11 2012-08-15 DeveloGen Aktiengesellschaft Verwendung von dg153 sekretierter proteinprodukte zur prevention und behandlung von pankreaserkrankungen und/oder fettleibigkeit und/oder metabolischem syndrom
CA2633468C (en) * 2005-12-14 2014-02-18 Licentia Ltd Novel neurotrophic factor protein and uses thereof
JP2011515489A (ja) * 2008-03-25 2011-05-19 アマランタス・セラピューティクス・インコーポレイテッド 神経変性障害
FI20080326A0 (fi) 2008-04-30 2008-04-30 Licentia Oy Neurotroofinen tekijä MANF ja sen käytöt
WO2011038366A1 (en) * 2009-09-25 2011-03-31 Amarantus Therapeutics, Inc. Dopaminergic selective factors
EP2717903B1 (de) 2011-06-09 2016-08-10 University Of Miami Die neurotrophischen faktoren manf und cdnf zur behandlung von netzhauterkrankungen
FI20115870A0 (fi) * 2011-09-05 2011-09-05 Urmas Arumaee Neuroprotektiiviset soluihin tunkeutuvat peptidit
KR20140121449A (ko) 2012-01-24 2014-10-15 유니버시티 오브 매사추세츠 췌장 베타-세포 장애에서의 가용성 ｍａｎｆ
WO2015149005A1 (en) * 2014-03-28 2015-10-01 Buck Institute For Research On Aging Methods and compositions for modulating the immune system
JP7201432B2 (ja) * 2015-11-18 2023-01-10 ヘランティス ファーマ ピーエルシー 中枢神経系疾患の鼻腔内治療に使用するためのｃｄｎｆまたはｍａｎｆを含む組成物
JP2021519578A (ja) * 2018-03-29 2021-08-12 ヘルシンギン ユリオピストＨｅｌｓｉｎｇｉｎ Ｙｌｉｏｐｉｓｔｏ Ｃ末端ｃｄｎｆ断片、それらを含む医薬組成物、並びにそれらの使用
CN113292656B (zh) * 2020-02-21 2022-10-25 四川大学华西医院 用于防治肥胖的中脑星形胶质细胞源性神经营养因子的融合蛋白

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1220681A2 (de) * 1999-09-16 2002-07-10 Prescient Neuropharma Inc. Überlebensfördernden neuronalen dopaminergischen faktoren und deren verwendungen
WO2001025427A1 (fr) * 1999-10-01 2001-04-12 Kyowa Hakko Kogyo Co., Ltd. Adn reagissant a la contrainte de cisaillement
EP1290005A4 (de) * 2000-03-21 2005-04-20 Curagen Corp Vegf-modulierte gene und verfahren, die diese verwenden
US20020182198A1 (en) 2001-03-20 2002-12-05 Commissiong John W. Dopaminergic neuronal survival-promoting factors and uses thereof
WO2002079246A2 (en) * 2001-03-30 2002-10-10 Geneprot, Inc. Human arginine-rich protein-related compositions
CA2458207A1 (en) * 2001-05-03 2002-11-14 Murdoch Childrens Research Institute Determination of a genetic predisposition for behavioural disorders
GB0113657D0 (en) * 2001-06-05 2001-07-25 Geneprot Inc Improved native chemical ligation with three or more components
US7452969B2 (en) 2002-08-30 2008-11-18 Licentia Ltd Neurotrophic factor protein and uses thereof
US20060195915A1 (en) 2002-08-30 2006-08-31 Licentia Ltd. Novel neurotrophic factor protein and uses thereof
JP2011515489A (ja) 2008-03-25 2011-05-19 アマランタス・セラピューティクス・インコーポレイテッド 神経変性障害
FI20080326A0 (fi) 2008-04-30 2008-04-30 Licentia Oy Neurotroofinen tekijä MANF ja sen käytöt
EP2717903B1 (de) 2011-06-09 2016-08-10 University Of Miami Die neurotrophischen faktoren manf und cdnf zur behandlung von netzhauterkrankungen

Also Published As

Publication number Publication date
EP1373502A2 (de) 2004-01-02
DK1373502T3 (da) 2011-01-10
ES2353490T3 (es) 2011-03-02
CA2441740A1 (en) 2002-09-26
EP1373502B8 (de) 2010-12-22
ATE485377T1 (de) 2010-11-15
JP2004528835A (ja) 2004-09-24
US8084425B2 (en) 2011-12-27
WO2002074956A3 (en) 2003-07-10
US20100119491A1 (en) 2010-05-13
US20020182198A1 (en) 2002-12-05
WO2002074956A2 (en) 2002-09-26
US20130078220A1 (en) 2013-03-28
US20160152673A1 (en) 2016-06-02
US20170298110A1 (en) 2017-10-19
EP1373502B1 (de) 2010-10-20
US9115208B2 (en) 2015-08-25

Similar Documents

Publication Publication Date Title
DE60238038D1 (de) Das Überleben dopaminerger Neuronen fördernde Faktoren und deren Verwendungen
ATE362766T1 (de) Apolipoprotein a-i agonisten sowie deren verwendung zur behandlung dislipidemischer erkrankungen
DE60238999D1 (de) Aminoindazolderivate mit kinaseinhibierender wirkung, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen
ES2188793T3 (es) Agente para el tratamiento de las enfermedades neurodegenerativas.
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
BR0315688A (pt) Compostos, composições farmacêuticas e seus usos no tratamento ou prevenção de doenças ou condições de proliferação celular metabólicas
BRPI0407662A (pt) derivados do ácido 1-fenilalcanocarboxìlico para o tratamento de doenças neurodegenerativas
DE60129943D1 (de) Differenzierung von knochenmarkzellen in neuronale zellen und deren verwendungen
NO20004803L (no) Smilagening og anzurogenin for behandling av Alzheimers sykdom
DE60335244D1 (de) Behandlung von verletzungen des zentralen nervensystems
ATE257390T1 (de) Verwendung eines bpi proteinproduktes als antithrombotisches mittel
NO20092741L (no) DR6-antagonister og anvendelse derav ved behandling av neurologiske forstyrrelser
BRPI0015533B8 (pt) enzima alfa-l-iduronidase humana recombinante, composição farmacêutica compreendendo a mesma e método para sua purificação
NO306779B1 (no) Naftalamider, anvendelse derav og farmasöytisk preparat
DE69528710D1 (de) 2-substituierte 1,2,5-thiadiazolidin-3-on-1,1-dioxiden, zusammensetzung und deren verwendung
BR0015416A (pt) Composições contendo derivados do ácido hidroxieicosa tetraenóico e métodos de uso no tratamento de distúrbios de olhos secos
DE69433309D1 (de) Verbeugende oder therapeutische Mittel für die Alzheimer-Krankheit, eine Siebtest-Methode, und die menschliche Tau-Protein-Kinase
ATE382366T1 (de) Modifizierte myelin proteinmoleküle
BRPI0415781A (pt) método para o tratamento de diabetes em um paciente e kit farmacêutico
DK1186672T3 (da) Polymorfismer i det humane gen for organiskaniontransporter C (OATP-C)
DE60037978D1 (de) Interferon ähnliche moleküle, und deren verwendungen
WO2001019851A3 (en) Opaminergic neuronal survival-promoting factors and uses thereof
ATE348158T1 (de) Neuartiges collectin
BR9811907A (pt) Proteìna de ligação de lactoferrina de neisseria
BRPI0409683A (pt) 5-hidroxiindóis com grupos n-óxido e seu emprego como agentes terapêuticos

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: AMARANTUS THERAPEUTICS, INC., PALO ALTO, CALIF, US